Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain Gelibter
Abstract
ALK-, ROS1- and NTRK-rearranged tumours represent a distinct clinical and molecular entity amongst non-small-cell lung cancer and have the highest frequency amongst young, non-smoker patients. This paper discusses ALK, ROS1 and NTRK-rearranged disease and all the available treatments are evaluated.
Topics & Concepts
CrizotinibROS1MedicineLung cancerALK inhibitorAdenocarcinomaAnaplastic lymphoma kinaseTargeted therapyCancer researchDiseaseTrk receptorOncologyInternal medicineCancerReceptorMalignant pleural effusionNeurotrophinLung Cancer Treatments and MutationsLung Cancer Research StudiesCholangiocarcinoma and Gallbladder Cancer Studies